Business Standard

SPONSORED CONTENT

What's this ?

Sponsored Content is a "Paid For" Press Release distribution arrangement. Purely a Commercial Arrangement, brands and advertisers pay to be featured and to get this content published.

The Editorial/Content team at Business Standard has not contributed to writing/editing this article.

To get your brand featured in this Section write to assist@bsmail.in

Fusion Health Care launches COVID-19 drug Favipiravir and an immunity booster

ANI Press Release 

Tennis player James Blake
Madhu Ramadugu, Managing Director, Fusion Health Care

Hyderabad (Telangana) [India], Aug 17 (ANI/BusinessWire India): Fusion Health Care Pvt Ltd, a leading innovative pharmaceutical company based at Hyderabad, has announced the launch of its Favipiravir drug under the brand name XARAVIR, for the treatment of mild to moderate COVID-19 cases.

"It gives us immense satisfaction to launch 'XARAVIR' as this drug has the potential to save precious lives. We have launched the product at an affordable price and strive to make it available in sufficient quantities to meet high demand for the drug in the Indian market," said Madhu Ramadugu, Managing Director.

"We have developed a good recognition in the Indian Pharmaceutical industry with frequent launch of innovative products. In June 2019, we have launched SCORBIX (Vitamin C 1.5 g injection) which is prominently used in the treatment of Sepsis backed up by clinical trials and global protocols. In the current pandemic situation, SCORBIX is used in the treatment of COVID patients due to its antiviral mechanisms and strong immunity build up. Presently, SCORBIX is widely used in all renowned Hospitals across India," said Krishnendu Paul, General Manager.

Fusion Health Care is known for its innovation - with many "First Time in India Products" which include - SCORBIX (Vitamin C 1.5 g Injection), DIFIDOX (Doxycycline Injection 100 mg) the No.1 brand in India predominantly used in treating dengue, malaria and fever of unknown origin, STAPHONEX (Flucloxacillin Injection 1 g/500 mg), ISEP (Isepamicin Injection 200/400 mg) and many more.

The company has recently launched an Immunity Booster product under the brand name D'FEND. It consists of Vitamin C 1000 mg plus Zinc 10 mg, available in sugar free orange flavour, in a tube of 20 effervescent tablets.

The role and benefits of Vitamin C plus Zinc have been published in many established journals that indicate to improve immunity and avoid Flu.

Marking its 13th anniversary, Fusion Health Care inaugurated its R & D Facility in Hyderabad to bring innovative and affordable products for Indian Market.

Fusion Health Care has a strong Pan-India presence with a field force of 600 employees and an innovative portfolio of Critical Care and Cardio-Diabetes products.

The company also has its own 24-Hour Help line "Fusion Cares" which will enhance the access to its products including XARAVIR (Favipiravir) during this tough times.

This story is provided by BusinessWire India. ANI will not be responsible in any way for the content of this article. (ANI/BusinessWire India)

DISCLAIMER


(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Mon, August 17 2020. 23:30 IST
RECOMMENDED FOR YOU

Fusion Health Care launches COVID-19 drug Favipiravir and an immunity booster

Hyderabad (Telangana) [India], Aug 17 (ANI/BusinessWire India): Fusion Health Care Pvt Ltd, a leading innovative pharmaceutical company based at Hyderabad, has announced the launch of its Favipiravir drug under the brand name XARAVIR, for the treatment of mild to moderate COVID-19 cases.

Hyderabad (Telangana) [India], Aug 17 (ANI/BusinessWire India): Fusion Health Care Pvt Ltd, a leading innovative pharmaceutical company based at Hyderabad, has announced the launch of its Favipiravir drug under the brand name XARAVIR, for the treatment of mild to moderate COVID-19 cases.

"It gives us immense satisfaction to launch 'XARAVIR' as this drug has the potential to save precious lives. We have launched the product at an affordable price and strive to make it available in sufficient quantities to meet high demand for the drug in the Indian market," said Madhu Ramadugu, Managing Director.

"We have developed a good recognition in the Indian Pharmaceutical industry with frequent launch of innovative products. In June 2019, we have launched SCORBIX (Vitamin C 1.5 g injection) which is prominently used in the treatment of Sepsis backed up by clinical trials and global protocols. In the current pandemic situation, SCORBIX is used in the treatment of COVID patients due to its antiviral mechanisms and strong immunity build up. Presently, SCORBIX is widely used in all renowned Hospitals across India," said Krishnendu Paul, General Manager.

Fusion Health Care is known for its innovation - with many "First Time in India Products" which include - SCORBIX (Vitamin C 1.5 g Injection), DIFIDOX (Doxycycline Injection 100 mg) the No.1 brand in India predominantly used in treating dengue, malaria and fever of unknown origin, STAPHONEX (Flucloxacillin Injection 1 g/500 mg), ISEP (Isepamicin Injection 200/400 mg) and many more.

The company has recently launched an Immunity Booster product under the brand name D'FEND. It consists of Vitamin C 1000 mg plus Zinc 10 mg, available in sugar free orange flavour, in a tube of 20 effervescent tablets.

The role and benefits of Vitamin C plus Zinc have been published in many established journals that indicate to improve immunity and avoid Flu.

Marking its 13th anniversary, Fusion Health Care inaugurated its R & D Facility in Hyderabad to bring innovative and affordable products for Indian Market.

Fusion Health Care has a strong Pan-India presence with a field force of 600 employees and an innovative portfolio of Critical Care and Cardio-Diabetes products.

The company also has its own 24-Hour Help line "Fusion Cares" which will enhance the access to its products including XARAVIR (Favipiravir) during this tough times.

This story is provided by BusinessWire India. ANI will not be responsible in any way for the content of this article. (ANI/BusinessWire India)

DISCLAIMER


(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
image
Business Standard
177 22

Fusion Health Care launches COVID-19 drug Favipiravir and an immunity booster

Hyderabad (Telangana) [India], Aug 17 (ANI/BusinessWire India): Fusion Health Care Pvt Ltd, a leading innovative pharmaceutical company based at Hyderabad, has announced the launch of its Favipiravir drug under the brand name XARAVIR, for the treatment of mild to moderate COVID-19 cases.

"It gives us immense satisfaction to launch 'XARAVIR' as this drug has the potential to save precious lives. We have launched the product at an affordable price and strive to make it available in sufficient quantities to meet high demand for the drug in the Indian market," said Madhu Ramadugu, Managing Director.

"We have developed a good recognition in the Indian Pharmaceutical industry with frequent launch of innovative products. In June 2019, we have launched SCORBIX (Vitamin C 1.5 g injection) which is prominently used in the treatment of Sepsis backed up by clinical trials and global protocols. In the current pandemic situation, SCORBIX is used in the treatment of COVID patients due to its antiviral mechanisms and strong immunity build up. Presently, SCORBIX is widely used in all renowned Hospitals across India," said Krishnendu Paul, General Manager.

Fusion Health Care is known for its innovation - with many "First Time in India Products" which include - SCORBIX (Vitamin C 1.5 g Injection), DIFIDOX (Doxycycline Injection 100 mg) the No.1 brand in India predominantly used in treating dengue, malaria and fever of unknown origin, STAPHONEX (Flucloxacillin Injection 1 g/500 mg), ISEP (Isepamicin Injection 200/400 mg) and many more.

The company has recently launched an Immunity Booster product under the brand name D'FEND. It consists of Vitamin C 1000 mg plus Zinc 10 mg, available in sugar free orange flavour, in a tube of 20 effervescent tablets.

The role and benefits of Vitamin C plus Zinc have been published in many established journals that indicate to improve immunity and avoid Flu.

Marking its 13th anniversary, Fusion Health Care inaugurated its R & D Facility in Hyderabad to bring innovative and affordable products for Indian Market.

Fusion Health Care has a strong Pan-India presence with a field force of 600 employees and an innovative portfolio of Critical Care and Cardio-Diabetes products.

The company also has its own 24-Hour Help line "Fusion Cares" which will enhance the access to its products including XARAVIR (Favipiravir) during this tough times.

This story is provided by BusinessWire India. ANI will not be responsible in any way for the content of this article. (ANI/BusinessWire India)

DISCLAIMER


(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22